$31.01
2.68% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US98419J2069
Symbol
XOMA
Sector
Industry

XOMA Corporation Stock price

$31.01
+1.50 5.08% 1M
+6.10 24.49% 6M
+12.51 67.62% YTD
+16.17 108.96% 1Y
+7.50 31.90% 3Y
+6.88 28.51% 5Y
-79.39 71.91% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.81 2.68%
ISIN
US98419J2069
Symbol
XOMA
Sector
Industry

Key metrics

Market capitalization $365.38m
Enterprise Value $341.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 15.80
P/S ratio (TTM) P/S ratio 16.91
P/B ratio (TTM) P/B ratio 4.30
Revenue growth (TTM) Revenue growth 389.82%
Revenue (TTM) Revenue $21.61m
EBIT (operating result TTM) EBIT $-15.40m
Free Cash Flow (TTM) Free Cash Flow $-15.55m
Cash position $142.92m
EPS (TTM) EPS $-3.48
P/E forward negative
P/S forward 12.85
EV/Sales forward 12.01
Short interest 2.16%
Show more

Is XOMA Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

XOMA Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a XOMA Corporation forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a XOMA Corporation forecast:

Buy
67%
Hold
33%

Financial data from XOMA Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
22 22
390% 390%
100%
- Direct Costs 0.23 0.23
75% 75%
1%
21 21
511% 511%
99%
- Selling and Administrative Expenses 35 35
39% 39%
160%
- Research and Development Expense 2.04 2.04
1,260% 1,260%
9%
-15 -15
29% 29%
-70%
- Depreciation and Amortization 0.23 0.23
75% 75%
1%
EBIT (Operating Income) EBIT -15 -15
31% 31%
-71%
Net Profit -30 -30
12% 12%
-139%

In millions USD.

Don't miss a Thing! We will send you all news about XOMA Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

XOMA Corporation Stock News

Neutral
GlobeNewsWire
19 days ago
Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio
Neutral
GlobeNewsWire
about one month ago
XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetiza...
Neutral
Business Wire
about one month ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Royal...
More XOMA Corporation News

Company Profile

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Head office United States
CEO Owen Hughes
Employees 13
Founded 1981
Website www.xoma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today